Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 92, Issue 1-2, 2004, Pages 63-71

  Kilker, Robin L ^a   Hartl, Michael W ^a   Rutherford, Tina M ^a   Planas Silva, Maricarmen D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Cyclin D1; Estrogen receptor; MCF 7; Tamoxifen resistance

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; PROTEIN PS2; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

MINK CELL FOCUS-FORMING VIRUS;

EID: 8444222836     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.05.005     Document Type: Article

References (74)

1. R. Clarke, M.C. Liu, K.B. Bouker, Z. Gu, R.Y. Lee, Y. Zhu, T.C. Skaar, B. Gomez, K. O'Brien, Y. Wang, and L.A. Hilakivi-Clarke Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 2003 7316 7339
2. S. Ali, and R.C. Coombes Endocrine-responsive breast cancer and strategies for combating resistance Nature Rev. Cancer 2 2002 101 112
3. A. Howell, D. DeFriend, J.F.R. Robertson, R.W. Blamey, and P. Walton Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer Lancet 345 1995 29 30
4. A. Howell, S.J. Howell, R. Clarke, and E. Anderson Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J. Steroid Biochem. Mol. Biol. 79 2001 227 237
5. D.A. Cameron, J.C. Keen, J.M. Dixon, C. Bellamy, A. Hanby, T.J. Anderson, and W.R. Miller Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes Eur. J. Cancer 36 2000 845 851
6. 1 phase Cancer Res. 43 1983 3583 3585
7. C.K. Osborne, K. Hobbs, and G.M. Clark Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice Cancer Res. 45 1985 584 590
8. C.K. Watts, K.J. Sweeney, A. Warlters, E.A. Musgrove, and R.L. Sutherland Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells Breast Cancer Res. Treat. 31 1994 95 105
9. 1-phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2 J. Biol. Chem. 272 1997 10882 10894
10. O.W.J. Prall, E.M. Rogan, E.A. Musgrove, C.K.W. Watts, and R.L. Sutherland c-Myc or cyclin D1 mimics estrogen effects on cyclin E-cdk2 activation and cell cycle re-entry Mol. Cell Biol. 18 1998 4499 4508
11. J.S. Foster, and J. Wimalasena Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells Mol. Endocrinol. 10 1996 488 498
12. M.D. Planas-Silva, and R.A. Weinberg Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution Mol. Cell Biol. 17 1997 4059 4069
13. 1-arrested human breast cancer cells Oncogene 12 1996 2315 2324
14. 1 checkpoint Mol. Cell Biol. 16 1996 6917 6925
15. J.S. Foster, D.C. Henley, A. Bukovsky, P. Seth, and J. Wimalasena Multifaceted regulation of cell cycle progression by estrogen: regulation of cdk inhibitors and cdc25A independent of cyclin D1-cdk4 function Mol. Cell Biol. 21 2001 794 810
16. C.K.W. Watts, A. Brady, B. Sarcevic, A. deFazio, E.A. Musgrove, and R.L. Sutherland Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation Mol. Endocrinol. 9 1995 1804 1813
17. X. Cui, and A.V. Lee Regulatory nodes that integrate and coordinate signaling as potential targets for breast cancer therapy Clin. Cancer Res. 10 2004 396s 401s
18. N.R.C. Wilcken, O.W.J. Prall, E.A. Musgrove, and R.L. Sutherland Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens Clin. Cancer Res. 3 1997 849 854
19. R. Hui, G.L. Finney, J.S. Carroll, C.S.L. Lee, E.A. Musgrove, and R.L. Sutherland Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogen in T-47D breast cancer cells Cancer Res. 62 2002 6916 6923
20. 1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells Oncogene 21 2002 8158 8165
21. R. Lu, and G. Serrero Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor) Proc. Natl. Acad. Sci. USA 98 2001 142 147
22. R. Hui, A.L. Cornish, R.A. McClelland, J.F.R. Robertson, R.W. Blamey, E.A. Musgrove, R.I. Nicholson, and R.L. Sutherland Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer Clin. Cancer Res. 2 1996 923 928
23. R. Hui, J.R. Ball, R.D. Macmillan, F.S. Kenny, O.W.J. Prall, D.H. Mampbell, A.L. Cornish, R.A. McClelland, R.J. Daly, J.F. Forbes, R.W. Blamey, E.A. Musgrove, J.F.R. Robertson, R.I. Nicholson, and R.L. Sutherland EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival Oncogene 17 1998 1053 1059
24. H. Olson, A. Borg, M. Fernö, J. Ranstam, and H. Siggurdsson Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones J. Natl. Cancer Inst. 83 1991 1483 1487
25. R. Seshadri, C.S.L. Lee, R. Hui, K. McCaul, D.J. Horsfall, and R.L. Sutherland cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis Clin. Cancer Res. 2 1996 1177 1184
26. I. Bieche, M. Olivi, C. Nogues, M. Vidau, and R. Lidereau Prognostic value of CCNDI gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays Br. J. Cancer 86 2002 580 586
27. A. Borg, H. Sigurdsson, G.M. Clark, M. Ferno, S.A.W. Fuqua, H. Olsson, D. Killander, and W.L. McGurie Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis Br. J. Cancer 13 1991 136 142
28. F.S. Kenny, R. Hui, E.A. Musgrove, J.M.W. Gee, R.W. Blamey, R.I. Nicholson, R.L. Sutherland, and J.F.R. Robertson Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer Clin. Cancer Res. 5 1999 2069 2076
29. A. Howell Faslodex (ICI 182780): an oestrogen receptor downregulator Eur. J. Cancer 36 2000 581 591
30. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
31. I.W. Taylor, P.J. Hoodson, M.D. Green, and R.L. Sutherland Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells Cancer Res. 43 1983 4007 4010
32. J.S. Carroll, O.W.J. Prall, E.A. Musgrove, and R.L. Sutherland A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence J. Biol. Chem. 275 2000 38221 38229
33. H. Varma, and S.E. Conrad Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain Oncogene 19 2000 4746 4753
34. R. Kumar, R.-A. Wang, A. Mazumdar, A.H. Talukder, M. Mandal, Z. Yang, R. Bagheri-Yarmand, A. Sahin, G. Hortobagyl, L. Adam, C.J. Barnes, and R.K. Vadlamudi A naturally ocurring MTA1 variant sequesters oestrogen receptot-α in the cytoplasm Nature 418 2002 654 657
35. R. Jakesz, C.A. Smith, S. Aitken, K. Huff, W. Schuette, S. Shackney, and M. Lippman Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells Cancer Res. 44 1984 619 625
36. J. Lukas, M. Pagano, Z. Staskova, G. Draetta, and J. Bartek Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cell lines Oncogene 9 1994 707 718
37. E.T. Alarid, N. Bakopoulos, and N. Solodin Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation Mol. Endocrinol. 13 1999 1522 1534
38. K. Christov, A. Ikui, A. Shilkaitis, A. Green, R. Yao, M. You, C. Grubbs, V. Steele, R. Lubet, and I.B. Weinstein Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors Breast Cancer Res. Treat. 77 2003 253 264
39. Cip1 Cancer Lett. 170 2001 109 116
40. M.D. Planas-Silva, J. Liu Donaher, and R.A. Weinberg Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression Cancer Res. 59 1999 4788 4792
41. L.C. Hodges, J.D. Cook, E.K. Lobenhofer, L. Li, L. Bennett, P.R. Bushel, C.M. Aldaz, C.A. Afshari, and C.L. Walker Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells Mol. Cancer Res. 1 2003 300 311
42. R. Clarke, F. Leonessa, J.N. Welch, and T.C. Skaar Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacol. Rev. 53 2001 25 71
43. N. Brunner, T.L. Frandsen, C. Holst-Hansen, M. Bei, E.W. Thompson, A.E. Wakeling, M.E. Lippman, and R. Clarke MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780 Cancer Res. 53 1993 3229 3232
44. A.E. Lykkesfeldt, and E.K. Sorensen Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1 Acta Oncol. 31 1992 131 138
45. X.F. Hu, M. Veroni, M. De Luise, A. Wakeling, R. Sutherlans, C.K.W. Watts, and J.R. Zalcberg Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780 Int. J. Cancer 55 1993 873 876
46. I.R. Hutcheson, J.M. Knowlden, T.-A. Madden, D. Barrow, J.M.W. Gee, A.E. Wakeling, and R.I. Nicholson Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res. Treat. 81 2003 81 93
47. M.E. Herman, and B.S. Katzenellenbogen Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen J. Steroid Biochem. Mol. Biol. 59 1996 121 134
48. R-1 Cancer Res. 54 1994 1587 1595
49. P. Coopman, M. Garcia, N. Brünner, D. Deroco, R. Clarke, and H. Rochefort Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells Int. J. Cancer 56 1994 295 300
50. B. Westley, F.E.B. May, A.M.C. Brown, A. Krust, P. Chambon, M.E. Lippman, and H. Rochefort Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines J. Biol. Chem. 259 1984 10030 10035
51. L.R. Wiseman, M.D. Johnson, A.E. Wakeling, A.E. Lykkesfeldt, F.E.B. May, and B.R. Westley Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells Eur. J. Cancer 29 1993 2256 2264
52. S.R.D. Johnston, G. Saccani-Joti, I.E. Smith, J. Salter, J. Newby, M. Coppen, S.R. Ebbs, and M. Dowsett Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res. 55 1995 3331 3338
53. S. Han, K. Park, B.N. Bae, K.H. Kim, H.J. Kim, Y.D. Kim, and H.Y. Kim Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer Oncol. Rep. 10 2003 141 144
54. C. Gelly, and J.R. Pasqualini Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone-sulfate to estradiol in the R-27 cells, a tamoxifen-resistant line derived from MCF-7 human breast cancer cells J. Steroid Biochem. 30 1988 321 324
55. D. Chen, E. Washbrook, N. Sarwar, G.J. Bates, P.E. Pace, V. Thirunuvakkarasu, J. Taylor, R.J. Epstein, F.V. Fuller-Pace, J.-M. Egly, R.C. Coombes, and S. Ali Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction patways revealed by phosphorylation-specific antisera Oncogene 21 2002 4921 4931
56. M. Dowsett Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer Endocr. Relat. Cancer 8 2001 191 195
57. J.M. Knowlden, I.R. Hutcheson, H.E. Jones, T. Madden, J.M.W. Gee, M.E. Harper, D. Barrow, A.E. Wakeling, and R.I. Nicholson Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediated an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 2003 1032 1044
58. H. Kurokawa, A.E.G. Lenferink, J.F. Simpson, P.I. Pisacane, and M.X. Sliwkowski Inhibition of HER2/neu (erb B-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res. 60 2000 5887 5894
59. H. Kurokawa, and C.L. Arteaga Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer Clin. Cancer Res. 7 2001 4436s 4442s
60. H. Kurokawa, and C.L. Arteaga ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms Clin. Cancer Res. 9 2003 511s 515s
61. A. Lipton, S.M. Ali, K. Leitzel, V. Chinchilli, L. Engle, H.A. Harvey, C. Brady, C.M. Nalin, M. Dugan, W. Carney, and J. Allard Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer J. Clin. Oncol. 20 2002 1467 1472
62. L.-A. Martin, I. Farmer, S.R.D. Johnston, S. Ali, C. Marshall, and M. Dowsett Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J. Biol. Chem. 278 2003 30458 30468
63. R.I. Nicholson, I.R. Hutcheson, J.M. Knowlden, H.E. Jones, M.E. Harper, N. Jordan, S.E. Hiscox, D. Barrow, and J.M.W. Gee Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination Clin. Cancer Res. 10 2004 346s 354s
64. R. Schiff, S.A. Massarweh, J. Shou, L. Bharwani, S.K. Mohsin, and C.K. Osborne Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin. Cancer Res. 10 2004 331s 336s
65. M.D. Planas-Silva, Y. Shang, J. Liu Donaher, M. Brown, and R.A. Weinberg AIB1 enhances estrogen-dependent induction of cyclin D1 expression Cancer Res. 61 2001 3858 3862
66. C.K. Osborne, V. Bardou, T.A. Hopp, G.C. Chamness, S.G. Hilsenbeck, S.A.W. Fuqua, J. Wong, D.C. Allred, G.M. Clark, and R. Schiff Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J. Natl. Cancer Inst. 95 2003 353 361
67. S.S. Larsen, M. Egeblad, M. Jaattela, and A.E. Lykkesfeldt Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family Breast Cancer Res. Treat. 58 1999 41 56
68. J.C. Newby, S.R.D. Johnston, I.E. Smith, and M. Dowsett Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer Clin. Cancer Res. 3 1997 1643 1651
69. E. Surmacz Function of the IGF-1 receptor in breast cancer J. Mam. Gland Biol. 5 2000 95 105
70. R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α J. Biol. Chem. 276 2001 9817 9824
71. A.S. Clark, K. West, S. Streicher, and P.A. Dennis Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol. Cancer Therap. 1 2002 707 717
72. J.P. Parisot, X.F. Hu, M. DeLuise, and J.R. Zalcberg Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line Br. J. Cancer 79 1999 693 700
73. P. Maxwell, and H.W. van den Berg Changes in the secretion of insulin-like growth factor binding proteins-2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cells lines Cancer Lett. 139 1999 121 127
74. Q. Yu, Y. Geng, and P. Sicinski Specific protection against breast cancers by cyclin D1 ablation Nature 411 2001 1017 1021